When it comes to clinical weight-loss treatments, GLP-1 therapies have taken the medical sector by storm. What started as off ...

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

Tirzepatide — a drug that acts both as a GLP-1 agonist and a GIP agonist — is the active ingredient in an even more powerful ...

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

PatchMD, a leading innovator in transdermal nutrient delivery, is excited to announce the launch of its new GLP-1 Support ...

Eli Lilly & Co. (NYSE: LLY) launched its own GLP-1/GIP dual agonist treatment for obesity, Zepbound, in December 2023. Zepbound is the most effective FDA-approved GLP-1 drug for weight loss.